Floatz logo

Pembrolizumab

Her2-Receptor Negative Breast Cancer

UNC Lineberger Comprehensive Cancer Centermonoclonal_antibodyPhase 2Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

185 Active assets in the Her2-Receptor Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
Exemestane
National Cancer Institute (NCI)
Phase 4BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Durvalumab
National Cancer Institute (NCI)
Phase 3BB
Docetaxel
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2/3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

progesterone-receptor negative breast cancerActive
BB
Indicative · Phase 2
71 / 100
View asset →
estrogen-receptor negative breast cancerActive
BB
Indicative · Phase 2
71 / 100
View asset →
gastroesophageal junction adenocarcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →